Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Tyra Biosciences, Inc. (TYRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $160.26 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-05-13
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $160.26M, a 1227.07% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $15.51M.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $229.00K.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $12.08M, a 62.54% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $285.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $160.26M 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $15.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.74M derived: sum of 2 quarters · filed 2025-11-05 | $27.82M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $12.30M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $12.08M 10-Q · filed 2025-05-08 | |||
| 2024-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $30.79M 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $32.24M 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | -$3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$591.00K derived: sum of 2 quarters · filed 2023-11-07 | $19.79M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $23.16M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $20.38M 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $6.47M 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $285.00K 10-K · filed 2022-03-03 | ||
| 2021-09-30 | $292.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |